(Page 2 of 2)
end development of its lung infection treatment meant for cystic fibrosis patients. Shares fell from $1.83 a piece to under a dollar, and midday Thursday they were trading at 52 cents.
—In a marriage of next-generation sequencing firms, Adaptive Biotechnologies of Seattle said Wednesday it has bought South San Francisco, CA-based Sequenta for an undisclosed sum of cash and stock. Adaptive also raised $94 million. The acquisition brings together two platforms for monitoring genetic changes in various cells of the immune system, as our former colleague Luke Timmerman explains here.
—San Diego-based GlySens, a medical device maker founded in 1998, raised $12 million from undisclosed investors in a Series C round of funding. The company plans to use the cash to advance its technology for a continuous glucose monitoring system, which includes a wireless sensor implanted under the skin for a year or more.
—San Diego’s Arena Pharmaceuticals (NASDAQ: ARNA) gained more than 76 percent, or $2.53 a share, in heavy trading Wednesday after reporting encouraging results from an early stage clinical trial of an autoimmune disorder treatment.
—San Diego’s Aethlon Medical (NASDAQ: AEMD) said the FDA will let the company conduct limited testing of its dialysis-like blood-filtration device in up to 20 Ebola-infected people in the U.S. In November, Aethlon said its hemopurifier helped an Ebola-infected doctor recover at Frankfurt University Hospital in Germany.
—Seattle’s Infectious Disease Research Institute has named former ZymoGenetics CEO Bruce Carter to its board and executive committee.
By posting a comment, you agree to our terms and conditions.